id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7205 R20461 |
Howren, 2020 | Congenital anomalies | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: Yes Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases | 6.58 [1.15;37.75] | -/- -/6,064 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10694 R39526 |
Cooper (Controls exposed to other treatment, sick), 2014 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases |
0.86 [0.11;6.73] C excluded (control group) |
1/23 19/379 | 20 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8721 R29503 |
Cooper (Controls unexposed, sick), 2014 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases | 1.96 [0.23;17.00] | 1/23 4/171 | 5 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6761 R41693 |
Dawson, 2014 | Major birth defects | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No Exposed group: MTX (polytherapy or not specified) Indications: Any or not specified | 1.83 [0.40;8.36] C | 10/12 27,613/37,724 | 27,623 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6775 R41697 |
Weber-Schoendorfer (Controls exposed to other treatment, sick), 2014 | Major birth defects | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: Yes Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases Matched |
1.80 [0.60;5.70] excluded (control group) |
7/106 14/393 | 21 | 106 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10347 R41698 |
Weber-Schoendorfer (Controls unexposed, disease free), 2014 | Major birth defects | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases Matched | 3.10 [1.03;9.50] | 7/106 29/1,001 | 36 | 106 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8745 R41736 |
Viktil (Controls exposed to other treatment, sick), 2012 | Major malformations | 3 months (or more) before pregnancy or during pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases |
1.85 [0.10;32.87] C excluded (control group) |
0/8 50/1,453 | 50 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10362 R41696 |
Viktil (Controls unexposed NOS), 2012 | Major malformations | at least 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No Exposed group: MTX (polytherapy or not specified) Indications: Inflammatory diseases | 10.00 [0.41;245.45] C | 0/2 5,000/154,976 | 5,000 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 3.16 [1.52;6.54] | 32,664 | 143 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Controls unexposed, disease free; 3: Controls unexposed NOS;
Asymetry test p-value = 0.5391 (by Egger's regression)
slope=0.5937 (0.8486); intercept=0.7060 (1.0214); t=0.6912; p=0.5391
excluded 8745, 10694, 6775